<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6"><labelDrug name="Caduet"><Normalization><mmtx cui="C1330119" preferredWord="Caduet" semType="phsu, orch"/></Normalization></labelDrug><generic name="amlodipine besylate and atorvastatin calcium"/><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1" text="CADUET (amlodipine besylate and atorvastatin calcium) tablet, film coated" type="negative"><entity charOffset="0:6" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.0" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><entity charOffset="32:52" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.1" text="atorvastatin calcium" type="Biomedical_Entity"><Normalization><mmtx cui="C0286650" phraseText="atorvastatin calcium" preferredWord="Atorvastatin calcium" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="8:27" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.2" text="amlodipine besylate" type="Biomedical_Entity"><Normalization><mmtx cui="C0354468" phraseText="(amlodipine besylate" preferredWord="Amlodipine Besylate" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.2"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.1.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2" text="CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate." type="negative"><entity charOffset="23:35" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.0" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="91:101" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.1" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="with both amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="0:6" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.2" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><entity charOffset="8:18" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.3" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="(amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="106:118" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.4" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.0"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.0"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.4"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.3"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.4"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.2.e.4"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.5" text="Dosage of CADUET must be individualized on the basis of both effectiveness and tolerance for each individual component in the treatment of hypertension/angina and hyperlipidemia. " type="negative"><entity charOffset="47:52" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.5.e.0" text="basis" type="Biomedical_Entity"><Normalization><mmtx cui="C1874451" phraseText="individualized on the basis of both effectiveness" preferredWord="Basis" semType="phsu"/><RxNorm RxCui="1046801"/></Normalization></entity><entity charOffset="10:16" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.5.e.1" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="Dosage of CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.5.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.5.e.0"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.6" text="Select doses of amlodipine and atorvastatin independently." type="negative"><entity charOffset="16:26" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.6.e.0" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="doses of amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="31:43" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.6.e.1" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin independently." preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.6.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.6.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8" text="Patients may be given the equivalent dose of CADUET or a dose of CADUET with increased amounts of amlodipine, atorvastatin, or both for additional antianginal effects, blood pressure lowering, or lipid-lowering effect." type="negative"><entity charOffset="65:71" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.0" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="a dose of CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><entity charOffset="147:158" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.1" text="antianginal" type="Biomedical_Entity"><Normalization><mmtx cui="C1874267" phraseText="both for additional antianginal effects," preferredWord="Anti-anginal [EPC]" semType="phsu"/><RxNorm RxCui="1447082"/></Normalization></entity><entity charOffset="110:122" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.2" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin," preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="98:108" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.3" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="of amlodipine," preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="45:51" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.4" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="the equivalent dose of CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.2"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.3"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.2"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.2"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.8.e.3"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.12" text="The usual initial antihypertensive oral dose of amlodipine is 5 mg once daily, and the maximum dose is 10 mg once daily." type="negative"><entity charOffset="48:58" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.12.e.0" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="The usual initial antihypertensive oral dose of amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="18:34" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.12.e.1" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="The usual initial antihypertensive oral dose of amlodipine" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.12.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.12.e.0"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.13" text="Pediatric (age &gt; 6 years), small adult, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other antihypertensive therapy." type="negative"><entity charOffset="203:219" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.13.e.0" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="adding amlodipine to other antihypertensive therapy." preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="183:193" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.13.e.1" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="adding amlodipine to other antihypertensive therapy." preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.13.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.13.e.0"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.21" text="Pediatrics: The effective antihypertensive oral dose of amlodipine in pediatric patients ages 6 17 years is 2.5 mg to 5 mg once daily. " type="negative"><entity charOffset="26:42" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.21.e.0" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="The effective antihypertensive oral dose of amlodipine" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="56:66" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.21.e.1" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="The effective antihypertensive oral dose of amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.21.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.21.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.32" text="Concomitant Lipid-Lowering Therapy: Atorvastatin may be used with bile acid resins. " type="negative"><entity charOffset="36:48" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.32.e.0" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="Atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="66:75" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.32.e.1" text="bile acid" type="Biomedical_Entity"><Normalization><mmtx cui="C2917673" phraseText="used with bile acid resins." preferredWord="Bile Acid [EPC]" semType="phsu"/><RxNorm RxCui="1540"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.32.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.32.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33" lineNumber="35" text="Monitor for signs of myopathy in patients receiving the combination of HMG-CoA reductase inhibitors (statins) and fibrates [see Warnings and Precautions (5.1), Drug Interactions (7)]." type="regular"><entity charOffset="0:7" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.0" text="Monitor" type="Caution_Interaction"/><entity charOffset="71:99" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.2" text="HMG-CoA reductase inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0360714" phraseText="the combination of HMG-CoA reductase inhibitors" preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="27274"/></Normalization></entity><entity charOffset="101:108" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.3" text="statins" type="Drug_Class"><Normalization><mmtx cui="C0360714" phraseText="(statins" preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><entity charOffset="114:122" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.5" text="fibrates" type="Drug_Class"><Normalization><mmtx cui="C1449704" phraseText="fibrates" preferredWord="Fibrates" semType="phsu, orch"/><RxNorm RxCui="1447103"/></Normalization></entity><classClassMembership drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.3"/><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.5" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.33.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="8" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36" lineNumber="39" text="Use with Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors: In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), avoid therapy with atorvastatin . In patients with HIV taking lopinavir plus ritonavir, use the lowest necessary dose of atorvastatin. " type="regular"><entity charOffset="228:233" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.0" text="avoid" type="Caution_Interaction"/><entity charOffset="104:116" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.2" text="cyclosporine" type="Drug"><Normalization><mmtx cui="C0010592" phraseText="cyclosporine" preferredWord="Cyclosporine" semType="phsu, aapp"/><RxNorm RxCui="3008"/></Normalization></entity><entity charOffset="124:147" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.3" text="HIV protease inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0162714" phraseText="the HIV protease inhibitors" preferredWord="HIV Protease Inhibitors" semType="phsu"/><RxNorm RxCui="40127"/></Normalization></entity><entity charOffset="149:174" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.4" text="tipranavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1977399" phraseText="(tipranavir plus ritonavir" preferredWord="Tipranavir+Ritonavir" semType="orch, antb"/><RxNorm RxCui="190548"/></Normalization></entity><entity charOffset="183:213" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.6" text="hepatitis C protease inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0033607" phraseText="the hepatitis C protease inhibitor" preferredWord="Protease Inhibitor" semType="bacs, phsu"/><mmtx cui="C3536890" phraseText="the hepatitis C protease inhibitor" preferredWord="Protease Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="989819"/></Normalization></entity><entity charOffset="215:225" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.7" text="telaprevir" type="Drug"><Normalization><mmtx cui="C1876229" phraseText="(telaprevir" preferredWord="telaprevir" semType="phsu, aapp"/><RxNorm RxCui="1102261"/></Normalization></entity><entity charOffset="247:259" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.9" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="therapy with atorvastatin ." preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="290:314" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.10" text="lopinavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C0939237" phraseText="with HIV taking lopinavir plus ritonavir," preferredWord="lopinavir / Ritonavir" semType="phsu, orch"/><RxNorm RxCui="195088"/></Normalization></entity><entity charOffset="349:361" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.11" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="the lowest necessary dose of atorvastatin." preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="316:345" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.12" text="use the lowest necessary dose" type="Caution_Interaction"/><entity charOffset="279:282" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.14" text="HIV" type="SPAN"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.4" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.3"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.7" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.6"/><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.7"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.4"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.ddi.2"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.12"><relations><relation type="hasContext"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.14"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.10"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.11"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.7"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.4"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.7"/><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.14" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.11" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.36.e.12" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="7" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37" lineNumber="39" text="In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, limit therapy with atorvastatin to 20 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed. " type="regular"><entity charOffset="19:33" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="35:47" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="69:72" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" text="HIV" type="SPAN"/><entity charOffset="97:122" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3" text="saquinavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1977397" phraseText="a combination of saquinavir plus ritonavir," preferredWord="Saquinavir+Ritonavir" semType="orch, antb"/><RxNorm RxCui="859857"/></Normalization></entity><entity charOffset="124:148" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4" text="darunavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1976853" phraseText="darunavir plus ritonavir," preferredWord="Darunavir+Ritonavir" semType="phsu, orch"/><RxNorm RxCui="460132"/></Normalization></entity><entity charOffset="150:163" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5" text="fosamprenavir" type="Drug"><Normalization><mmtx cui="C1176315" phraseText="fosamprenavir," preferredWord="fosamprenavir" semType="phsu, orch"/><RxNorm RxCui="358262"/></Normalization></entity><entity charOffset="168:196" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6" text="fosamprenavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1979439" phraseText="fosamprenavir plus ritonavir," preferredWord="Fosamprenavir+Ritonavir" semType="phsu, orch"/><RxNorm RxCui="358262"/></Normalization></entity><entity charOffset="198:203" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" text="limit" type="Caution_Interaction"/><entity charOffset="217:229" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="limit therapy with atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" type="Caution_Interaction"/><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" type="Caution_Interaction"/><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" type="Caution_Interaction"/><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" type="Caution_Interaction"/><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" type="Caution_Interaction"/><pair context="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.2" ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.7" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.37.e.5"/></sentence><sentence biomedicalEntities="5" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38" lineNumber="39" text="In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, limit therapy with atorvastatin to 40 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed [see Warnings and Precautions (5.1), Drug Interactions (7.13)]." type="regular"><entity charOffset="23:45" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.0" text="HIV protease inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0162714" phraseText="the HIV protease inhibitor nelfinavir" preferredWord="HIV Protease Inhibitors" semType="phsu"/><mmtx cui="C3536890" phraseText="the HIV protease inhibitor nelfinavir" preferredWord="Protease Inhibitor [EPC]" semType="phsu"/><mmtx cui="C3536912" phraseText="the HIV protease inhibitor nelfinavir" preferredWord="Human Immunodeficiency Virus Protease Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="40127"/></Normalization></entity><entity charOffset="46:56" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.1" text="nelfinavir" type="Drug"><Normalization><mmtx cui="C0525005" phraseText="the HIV protease inhibitor nelfinavir" preferredWord="Nelfinavir" semType="phsu, orch"/><mmtx cui="C0525005" phraseText="the HIV protease inhibitor nelfinavir" preferredWord="Nelfinavir" semType="phsu, orch"/><mmtx cui="C0525005" phraseText="the HIV protease inhibitor nelfinavir" preferredWord="Nelfinavir" semType="phsu, orch"/><RxNorm RxCui="266565"/></Normalization></entity><entity charOffset="64:94" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.3" text="hepatitis C protease inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0033607" phraseText="the hepatitis C protease inhibitor boceprevir," preferredWord="Protease Inhibitor" semType="bacs, phsu"/><mmtx cui="C3536890" phraseText="the hepatitis C protease inhibitor boceprevir," preferredWord="Protease Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="989819"/></Normalization></entity><entity charOffset="95:105" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.4" text="boceprevir" type="Drug"><Normalization><mmtx cui="C1738934" phraseText="the hepatitis C protease inhibitor boceprevir," preferredWord="boceprevir" semType="bacs, phsu, aapp"/><mmtx cui="C1738934" phraseText="the hepatitis C protease inhibitor boceprevir," preferredWord="boceprevir" semType="bacs, phsu, aapp"/><RxNorm RxCui="1102129"/></Normalization></entity><entity charOffset="107:112" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.6" text="limit" type="Caution_Interaction"/><entity charOffset="126:138" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.8" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="limit therapy with atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.1" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.0"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.4" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.3"/><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.8"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.8" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.6" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.8" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.6" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.38.e.4"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.54" text="CADUET should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazard. " type="negative"><entity charOffset="0:6" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.54.e.0" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><entity charOffset="129:137" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.54.e.1" text="informed" type="Biomedical_Entity"><Normalization><mmtx cui="C0537670" phraseText="informed of the potential hazard." preferredWord="Oprelvekin" semType="phsu, aapp, imft"/><RxNorm RxCui="217731"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.54.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.54.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.57" text="It is not known whether atorvastatin or amlodipine are excreted into human milk; " type="negative"><entity charOffset="40:50" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.57.e.0" text="amlodipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0051696" phraseText="amlodipine" preferredWord="Amlodipine" semType="phsu, orch"/><RxNorm RxCui="104416"/></Normalization></entity><entity charOffset="24:36" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.57.e.1" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.57.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.57.e.0"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.59" text="Because statins have the potential for serious adverse reactions in nursing infants, women taking CADUET should not breastfeed their infants [see Specific Populations (8.3)]." type="negative"><entity charOffset="98:104" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.59.e.0" text="caduet" type="Biomedical_Entity"><Normalization><mmtx cui="C1330119" phraseText="CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><entity charOffset="8:15" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.59.e.1" text="statins" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="statins" preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.59.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.59.e.0"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.65" text="Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times upper limit of normal [ULN]. " type="negative"><entity charOffset="0:12" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.65.e.0" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="Atorvastatin," preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="25:32" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.65.e.1" text="statins" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="like other statins," preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.65.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.65.e.1"/></sentence><sentence biomedicalEntities="6" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66" lineNumber="65" text="The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis." type="regular"><entity charOffset="39:51" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.0" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="The concomitant use of higher doses of atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="79:91" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.1" text="cyclosporine" type="Drug"><Normalization><mmtx cui="C0010592" phraseText="such as cyclosporine" preferredWord="Cyclosporine" semType="phsu, aapp"/><RxNorm RxCui="3008"/></Normalization></entity><entity charOffset="96:120" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2" text="strong CYP3A4 inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="608507"/></Normalization></entity><entity charOffset="128:142" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.3" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="144:156" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.4" text="itraconazole" type="Drug"><Normalization><mmtx cui="C0064113" phraseText="itraconazole," preferredWord="Itraconazole" semType="phsu, orch"/><RxNorm RxCui="28031"/></Normalization></entity><entity charOffset="162:185" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.5" text="HIV protease inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0162714" phraseText="HIV protease inhibitors" preferredWord="HIV Protease Inhibitors" semType="phsu"/><RxNorm RxCui="40127"/></Normalization></entity><entity charOffset="209:217" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.9" text="myopathy" type="Specific_Interaction"><Normalization><mmtx cui="C0026848" phraseText="the risk of myopathy/rhabdomyolysis." preferredWord="Myopathy" semType="dsyn"/></Normalization></entity><entity charOffset="218:232" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.11" text="rhabdomyolysis" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.3" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.4" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2"/><classClassMembership drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.5"/><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.9"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.ddi.2"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.11"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.9" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.1" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.9" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.66.e.2"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.67" text="There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. " type="negative"><entity charOffset="39:47" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.67.e.0" text="mediated" type="Biomedical_Entity"><Normalization><mmtx cui="C0127400" phraseText="rare reports of immune-mediated necrotizing myopathy (IMNM)," preferredWord="Mediator brand of benfluorex hydrochloride" semType="phsu, orch"/><RxNorm RxCui="985488"/></Normalization></entity><entity charOffset="117:123" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.67.e.1" text="statin" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="associated with statin use." preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.67.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.67.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.68" text="IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; " type="negative"><entity charOffset="128:134" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.68.e.0" text="statin" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="persist despite discontinuation of statin treatment" preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><entity charOffset="0:4" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.68.e.1" text="imnm" type="Biomedical_Entity"><Normalization><mmtx cui="C0127400" phraseText="IMNM" preferredWord="Mediator brand of benfluorex hydrochloride" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.68.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.68.e.0"/></sentence><sentence biomedicalEntities="16" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74" lineNumber="71" text="The risk of myopathy during treatment with statins is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. " type="regular"><entity charOffset="12:20" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" text="myopathy" type="Specific_Interaction"><Normalization><mmtx cui="C0026848" phraseText="The risk of myopathy" preferredWord="Myopathy" semType="dsyn"/></Normalization></entity><entity charOffset="43:50" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" text="statins" type="Drug_Class"><Normalization><mmtx cui="C0360714" phraseText="with statins" preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><entity charOffset="98:110" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" text="cyclosporine" type="Drug"><Normalization><mmtx cui="C0010592" phraseText="increased with concurrent administration of cyclosporine," preferredWord="Cyclosporine" semType="phsu, aapp"/><RxNorm RxCui="3008"/></Normalization></entity><entity charOffset="112:135" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" text="fibric acid derivatives" type="Drug_Class"><Normalization><mmtx cui="C0604300" phraseText="fibric acid derivatives," preferredWord="fibric acid" semType="phsu, orch"/><RxNorm RxCui="1029707"/></Normalization></entity><entity charOffset="137:149" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin," preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="151:165" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="171:201" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.7" text="hepatitis C protease inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0033607" phraseText="the hepatitis C protease inhibitor telaprevir," preferredWord="Protease Inhibitor" semType="bacs, phsu"/><mmtx cui="C3536890" phraseText="the hepatitis C protease inhibitor telaprevir," preferredWord="Protease Inhibitor [EPC]" semType="phsu"/><RxNorm RxCui="989819"/></Normalization></entity><entity charOffset="202:212" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8" text="telaprevir" type="Drug"><Normalization><mmtx cui="C1876229" phraseText="the hepatitis C protease inhibitor telaprevir," preferredWord="telaprevir" semType="phsu, aapp"/><mmtx cui="C1876229" phraseText="the hepatitis C protease inhibitor telaprevir," preferredWord="telaprevir" semType="phsu, aapp"/><RxNorm RxCui="1102261"/></Normalization></entity><entity charOffset="214:253" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10" text="combinations of HIV protease inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0162714" phraseText="combinations of HIV protease inhibitors," preferredWord="HIV Protease Inhibitors" semType="phsu"/><RxNorm RxCui="1429321"/></Normalization></entity><entity charOffset="265:290" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.11" text="saquinavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1977397" phraseText="saquinavir plus ritonavir," preferredWord="Saquinavir+Ritonavir" semType="orch, antb"/><RxNorm RxCui="859857"/></Normalization></entity><entity charOffset="292:316" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.12" text="lopinavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C0939237" phraseText="lopinavir plus ritonavir," preferredWord="lopinavir / Ritonavir" semType="phsu, orch"/><RxNorm RxCui="195088"/></Normalization></entity><entity charOffset="318:343" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.13" text="tipranavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1977399" phraseText="tipranavir plus ritonavir," preferredWord="Tipranavir+Ritonavir" semType="orch, antb"/><RxNorm RxCui="190548"/></Normalization></entity><entity charOffset="345:369" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.14" text="darunavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1976853" phraseText="darunavir plus ritonavir," preferredWord="Darunavir+Ritonavir" semType="phsu, orch"/><RxNorm RxCui="460132"/></Normalization></entity><entity charOffset="371:384" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.15" text="fosamprenavir" type="Drug"><Normalization><mmtx cui="C1176315" phraseText="fosamprenavir," preferredWord="fosamprenavir" semType="phsu, orch"/><RxNorm RxCui="358262"/></Normalization></entity><entity charOffset="390:418" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.16" text="fosamprenavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1979439" phraseText="fosamprenavir plus ritonavir," preferredWord="Fosamprenavir+Ritonavir" semType="phsu, orch"/><RxNorm RxCui="358262"/></Normalization></entity><entity charOffset="420:426" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17" text="niacin" type="Drug"><Normalization><mmtx cui="C0027996" phraseText="niacin," preferredWord="Niacin" semType="phsu, orch, vita"/><RxNorm RxCui="7393"/></Normalization></entity><entity charOffset="431:448" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18" text="azole antifungals" type="Drug_Class"><Normalization><mmtx cui="C0360363" phraseText="azole antifungals." preferredWord="Azole antifungal" semType="phsu, orch"/><RxNorm RxCui="1269"/></Normalization></entity><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.7"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.11" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.12" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.13" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.14" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.15" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.16" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.0" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.5"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.18"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.17"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.3" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.74.e.4"/></sentence><sentence biomedicalEntities="11" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" lineNumber="71" text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. " type="regular"><entity charOffset="326:364" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" text="weigh the potential benefits and risks" type="Caution_Interaction"/><entity charOffset="386:393" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.2" text="monitor" type="Caution_Interaction"/><entity charOffset="45:51" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" text="CADUET" type="Drug"><Normalization><mmtx cui="C1330119" phraseText="combined therapy with CADUET" preferredWord="Caduet" semType="phsu, orch"/><RxNorm RxCui="404914"/></Normalization></entity><entity charOffset="56:79" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" text="fibric acid derivatives" type="Drug_Class"><Normalization><mmtx cui="C0604300" phraseText="fibric acid derivatives," preferredWord="fibric acid" semType="phsu, orch"/><RxNorm RxCui="1029707"/></Normalization></entity><entity charOffset="81:93" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin," preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="95:109" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="128:153" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" text="saquinavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1977397" phraseText="a combination of saquinavir plus ritonavir," preferredWord="Saquinavir+Ritonavir" semType="orch, antb"/><RxNorm RxCui="859857"/></Normalization></entity><entity charOffset="155:179" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" text="lopinavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C0939237" phraseText="lopinavir plus ritonavir," preferredWord="lopinavir / Ritonavir" semType="phsu, orch"/><RxNorm RxCui="195088"/></Normalization></entity><entity charOffset="181:205" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" text="darunavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1976853" phraseText="darunavir plus ritonavir," preferredWord="Darunavir+Ritonavir" semType="phsu, orch"/><RxNorm RxCui="460132"/></Normalization></entity><entity charOffset="207:220" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11" text="fosamprenavir" type="Drug"><Normalization><mmtx cui="C1176315" phraseText="fosamprenavir," preferredWord="fosamprenavir" semType="phsu, orch"/><RxNorm RxCui="358262"/></Normalization></entity><entity charOffset="225:253" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12" text="fosamprenavir plus ritonavir" type="Drug"><Normalization><mmtx cui="C1979439" phraseText="fosamprenavir plus ritonavir," preferredWord="Fosamprenavir+Ritonavir" semType="phsu, orch"/><RxNorm RxCui="358262"/></Normalization></entity><entity charOffset="255:272" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13" text="azole antifungals" type="Drug_Class"><Normalization><mmtx cui="C0360363" phraseText="azole antifungals," preferredWord="Azole antifungal" semType="phsu, orch"/><RxNorm RxCui="1269"/></Normalization></entity><entity charOffset="302:308" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14" text="niacin" type="Drug"><Normalization><mmtx cui="C0027996" phraseText="lipid-modifying doses of niacin" preferredWord="Niacin" semType="phsu, orch, vita"/><RxNorm RxCui="7393"/></Normalization></entity><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.ddi.2"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11"/></sentence><sentence biomedicalEntities="1" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76" lineNumber="71" text="Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [see Drug Interactions (7.13)]. " type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="56:79" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.5" text="fibric acid derivatives" type="Drug_Class"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="81:93" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.6" text="erythromycin" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="95:109" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.7" text="clarithromycin" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="128:153" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.8" text="saquinavir plus ritonavir" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="155:179" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.9" text="lopinavir plus ritonavir" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="181:205" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.10" text="darunavir plus ritonavir" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="207:220" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.11" text="fosamprenavir" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="225:253" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.12" text="fosamprenavir plus ritonavir" type="Drug"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="255:272" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.13" text="azole antifungals" type="Drug_Class"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75" Text="Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. "/><anaphoraEntity charOffset="108:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" text="aforementioned drugs" type="Expression"/><antecedentEntity charOffset="302:308" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.75.e.14" text="niacin" type="Drug"/></anaphoraRelation><entity charOffset="31:36|0:14" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.0" text="doses Lower starting" type="Caution_Interaction"/><entity charOffset="19:36|0:5" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.2" text="maintenance doses Lower" type="Caution_Interaction"/><entity charOffset="40:52" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.4" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="maintenance doses of atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.4"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.ddi.2"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.5" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.76.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78" lineNumber="73" text="Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see Drug Interactions (7.23)]." type="regular"><entity charOffset="9:17" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.0" text="myopathy" type="Specific_Interaction"><Normalization><mmtx cui="C0026848" phraseText="Cases of myopathy," preferredWord="Myopathy" semType="dsyn"/></Normalization></entity><entity charOffset="29:43" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.2" text="rhabdomyolysis" type="Specific_Interaction"/><entity charOffset="69:81" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.4" text="atorvastatin" type="Drug"><Normalization><mmtx cui="C0286651" phraseText="reported with atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="103:113" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.5" text="colchicine" type="Drug"><Normalization><mmtx cui="C0009262" phraseText="co-administered with colchicine," preferredWord="Colchicine" semType="phsu, orch"/><RxNorm RxCui="2683"/></Normalization></entity><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.0"><relations><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.5"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.ddi.2"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.2"><relations><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.5" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.78.e.0" type="Specific_Interaction"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.81" text="Statins, like atorvastatin, and some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. " type="negative"><entity charOffset="14:26" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.81.e.0" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="like atorvastatin," preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.81.e.1" text="statins" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="Statins," preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.81.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.81.e.0"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.89" text="There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. " type="negative"><entity charOffset="101:108" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.89.e.0" text="statins" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="statins," preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><entity charOffset="120:132" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.89.e.1" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin." preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.89.e.0" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.89.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99" text="Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin." type="negative"><entity charOffset="116:128" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.0" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin." preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="76:104" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.1" text="hmg-coa reductase inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0360714" phraseText="reported with HMG-CoA reductase inhibitors," preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="27274"/></Normalization></entity><entity charOffset="37:44" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.2" text="glucose" type="Biomedical_Entity"><Normalization><mmtx cui="C0017725" phraseText="fasting serum glucose levels" preferredWord="Glucose" semType="bacs, phsu, carb"/><RxNorm RxCui="4850"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.0"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.0"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.99.e.1"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.101" text="Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. " type="negative"><entity charOffset="75:83" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.101.e.0" text="cortisol" type="Biomedical_Entity"><Normalization><mmtx cui="C0020268" phraseText="basal plasma cortisol concentration" preferredWord="Hydrocortisone" semType="strd, phsu, horm"/><RxNorm RxCui="5492"/></Normalization></entity><entity charOffset="33:45" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.101.e.1" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="that atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.101.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.101.e.0"/></sentence><sentence biomedicalEntities="5" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104" lineNumber="99" text="Avoid a statin with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine." type="regular"><entity charOffset="20:97" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.0" text="drugs that may decrease the levels or activity of endogenous steroid hormones" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="a statin with drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><mmtx cui="C2946261" phraseText="the levels" preferredWord="Level" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="106:118" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.1" text="ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="such as ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="120:134" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.2" text="spironolactone" type="Drug"><Normalization><mmtx cui="C0037982" phraseText="spironolactone," preferredWord="Spironolactone" semType="strd, phsu"/><RxNorm RxCui="9997"/></Normalization></entity><entity charOffset="140:150" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.3" text="cimetidine" type="Drug"><Normalization><mmtx cui="C0008783" phraseText="cimetidine." preferredWord="Cimetidine" semType="phsu, orch"/><RxNorm RxCui="2541"/></Normalization></entity><entity charOffset="8:14" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.4" text="statin" type="Drug_Class"><Normalization><mmtx cui="C0360714" phraseText="a statin with drugs" preferredWord="Hydroxymethylglutaryl-CoA Reductase Inhibitors" semType="phsu, orch"/><RxNorm RxCui="108229"/></Normalization></entity><entity charOffset="0:5" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.5" text="Avoid" type="Caution_Interaction"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.1" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.0"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.2" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.0"/><drugClassMembership drug="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.3" drugClass="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.0"/><drugInteraction id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.ddi.1"><interaction trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.5"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.4" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.0" trigger="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.104.e.5" type="Caution_Interaction"/></sentence><sentence id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115" text="In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. " type="negative"><entity charOffset="360:372" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.0" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="2.3% atorvastatin" preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="115:133" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.1" text="atorvastatin 80 mg" type="Biomedical_Entity"><Normalization><mmtx cui="C1124482" phraseText="where atorvastatin 80 mg" preferredWord="atorvastatin 80 MG" semType="clnd"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="305:323" id="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.2" text="atorvastatin 80 mg" type="Biomedical_Entity"><Normalization><mmtx cui="C1124482" phraseText="seen in the atorvastatin 80 mg group" preferredWord="atorvastatin 80 MG" semType="clnd"/><RxNorm RxCui="83367"/></Normalization></entity><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.1" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.0"/><pair ddi="false" e1="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.2" e2="Dailymed.6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6.s.115.e.0"/></sentence><positiveExamples number="36"/><negativeExamples number="133"/></document>